Advancing Atrial Fibrillation Therapy
Healium Medical develops no-contact guided ablation system for treatment of atrial fibrillation – the most common cardiac arrhythmia affecting more than 46.1 Million patients worldwide.
The company develops transcatheter ultrasound technology enabling rapid, no-contact circumferential
pulmonary vein isolation with real-time lesion monitoring. Our goal is to improve procedure efficacy
simplify procedure flow and shorten procedure time.
The company operates out of Yokneam, Israel, have full scale in-house R&D lab, employs multidisciplinary team of physicist, engineers & physicians and have pre-clinical data supporting the feasibility of its proprietary technology.
Description of Atrial Fibrillation:
Atrial fibrillation (AF or Afib for short) is the most
common cardiac arrhythmia or rhythm abnormality.
AF is an irregular and often rapid heart rate that may cause symptoms like heart palpitations, fatigue, and shortness of breath. AF occurs when the upper chambers of the heart (atria) beat rapidly and irregularly (fibrillate). This can cause blood to pool and form clots in an area of the heart called the left atrial appendage (LAA).
When a blood clot escapes from the LAA and travels
to another part of the body, it can cause a stroke.
These who have AF X5 times more likely to suffer a stroke than someone with a regular heartbeat.
Fortunately, AF may be treated with medication, cardioversion or a catheter ablation procedure. However, Despite the large number of advances in the field over the past two decades, AF remains a substantial cause of mortality and morbidity
Atrial Fibrillation Heart
5x Risk of Stroke
for patients with AF
lead to blood
90% of trigers found in the pul-monary vein
Catheter Ablation | Cornerstone of AF Treatment
Electrical isolation of the
four pulmonary veins
Ablation catheters create lesions around the pulmonary veins to block electrical triggers
Poor / No
No lesion monitoring lesions
Close to 40% of patients will required 2nd procedure over
time due to key technological limitations of existing approved products.
of the diagnosed symptomatic AF patient population
per yearin the US alone
2013 - 2016
M&A Since 2008